Vical Announces Breakthrough for Pandemic Influenza DNA Vaccines With Preliminary ...(rivalent vaccines or for the needle orne...),Health

Date:7/16/2008

rivalent vaccines or for the needle or needle-free injection methods; whether Vical or others will secure funding to advance the pandemic influenza DNA vaccine program; whether commercial partners or collaborators will pursue additional Vaxfectin(R) applications; whether any product candidates will be shown to be safe and efficacious in clinical trials; the timing of clinical trials; whether Vical or its collaborative partners will seek or gain approval to market any product candidates; the dependence of the company on its collaborative partners; and additional risks set forth in the company's filings with the Securities and Exchange Commission. These forward-looking statements represent the company's judgment as of the date of this release. The company disclaims, however, any intent or obligation to update these forward-looking statements.

Contacts: Investors: Media:

Alan R. Engbring Heidi Chokeir, Ph.D., or David Schull

Vical Incorporated Russo Partners

(858) 646-1127 (619) 814-3512

aengbring@vical.com heidi.chokeir@russopartnersllc.com

Website: http://www.vical.com

'/>"/>

SOURCE Vical Incorporated Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6
Related medicine technology :

1. Vical Advances RapidResponse(TM) DNA Vaccine Platform Under $6 Million Grant from NIH
2. Vical Receives $6.3 Million Payment for Continued Funding of Allovectin-7(R) Phase 3 Trial
3. Ending Cervical Cancer Featured at Summit; QIAGEN CEO Issues a Call to Global Women Leaders
4. Promise of Vicals CMV Vaccine Noted by Independent Experts
5. Study Finds QIAGENs HPV Test Offers Greater Long-term Protection From Cervical Disease Than the Pap
6. Nventa Announces Additional Positive Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial
7. Globus Medical Completes Enrollment Of SECURE(R)-C Cervical Artificial Disc Clinical Trial
8. Nventa Completes Safety Evaluation on Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
9. Vical Promotes Melanoma Awareness Month With Allovectin-7(R) Video Report
10. Vical Receives NIH Grant for an Immunotherapeutic Herpes DNA Vaccine; Herpes Experts at University of Washington and University of Texas to Conduct Preclinical Development
11. Gen-Probe Begins U.S. Clinical Study of Molecular Test for Human Papillomavirus, Which Causes Cervical Cancer